In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits
The incidence of heart failure, silent ischaemia and arrhythmias are higher in patients with T2DM and GPs need a high index of suspicion to identify, diagnose and treat these

 


Host: Dr David Lim | Total time: 27 mins

Guest: A/Prof Neale Cohen, Endocrinologist; Director of Clinical Diabetes, the Baker Heart and Diabetes Institute, Melbourne


Register for our fortnightly FREE WEBCASTS

Every second Tuesday | 7:00pm-9:00pm AEST

Click here to register for the next one

<ul>
<li>In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits</li>
<li>The incidence of heart failure, silent ischaemia and arrhythmias are higher in patients with T2DM and GPs need a high index of suspicion to identify, diagnose and treat these</li>
</ul>
&nbsp;
 Host: Dr David Lim | Total time: 27 mins
Guest: A/Prof Neale Cohen, Endocrinologist; Director of Clinical Diabetes, the Baker Heart and Diabetes Institute, Melbourne
 Register for our fortnightly FREE WEBCASTS
Every second Tuesday | 7:00pm-9:00pm AEST
<a href="https://www.healthed.com.au/webcast/">Click here to register for the next one</a>

Healthed's medical education channel features the latest high quality clinical interviews and lectures from leading experts in their field, offering health professionals a convenient new way to boost their knowledge.

Advertisement